FINHUB Insights

DVA · Q2 FY25 · Apr 1 – Jun 30, 2025

DaVita Q2 FY25: where the revenue came from and where it went

DaVita Q2 FY25: revenue $3.4B (+6% year over year). Net profit $0.2B. Largest cohort U.S.Dialysis and Related Lab $2.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 5, 2025 10-Q
Sankey diagram of DaVita's income statement for Q2 FY25: revenue of $3.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.4B +6% year over year
Operating profit$0.5B 16% margin
Net profit$0.2B 6% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.4 100% +6%
U.S.Dialysis and Related Lab 2.9 85% +2%
All Other Segments 0.5 15% +35%
Patient care−2.267%+0pp
General and administrative−0.412%+0pp
Depreciation and amortization−0.25%+0pp
Operating profit0.516% margin+0pp
Tax−0.1
Interest & other costs−0.2
Net profit0.26%−1pp
Filing on EDGAR More quarters of DVA

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters